precisionmedicineonline8d
Bristol Myers Squibb Focused on Opdivo SubQ Growth as Q4 Precision Product Sales Increase
Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.
Seeking Alpha14d
Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data
Elicio Therapeutics (NASDAQ:ELTX) recently announced a $10 million registered direct offering. The stock is trading lower by 10% on the back of this news. However, despite this, I believe that ...
FiercePharma20d
Bristol Myers, Pfizer tout new standards of care in colorectal cancer subtypes
Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them as new standard treatments for certain colorectal cancer patients.
FiercePharma29d
AstraZeneca's Calquence and Amgen's Lumakras clinch FDA label expansions
BMS, Mirati's Krazati cements lead over Amgen's Lumakras with FDA approval in colorectal cancer As for Amgen, the company’s Lumakras and Vectibix combination was granted approval to treat ...
Reuters29d
US FDA approves Amgen's colorectal cancer therapy
Jan 16 (Reuters) - The U.S. Food and Drug Administration approved Amgen's (AMGN.O), opens new tab combination therapy on Thursday to treat colorectal cancer in patients with a specific gene ...
The Pharma Letter29d
FDA nod for Lumakras with Vectibix combo for mCRC
The US Food and Drug Administration approved sotorasib (trade name Lumakras) with panitumumab Vectibix), from US biotech major Amgen (Nasdaq: AMGN), for adult patients with KRAS G12C-mutated ...